Checkpoint Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Checkpoint Therapeutics generated cash of -$47,590,000, which is more than the previous year. Cash used in financing activities reached the amount of $40,450,000 last year. Net change in cash is therefore -$7,140,000.
Cash Flow
| 2015 | -1.10M | -2.52M | 54.05M |
|---|---|---|---|
| 2016 | -9.95M | -3.16M | -2.22M |
| 2017 | -15.46M | -400K | 0 |
| 2018 | -25.80M | 0 | 28.57M |
| 2019 | -21.37M | 0 | 25.45M |
| 2020 | -16.55M | 0 | 31.24M |
| 2021 | -26.30M | 0 | 40.26M |
| 2022 | -57.55M | 0 | 14.88M |
| 2023 | -47.59M | 0 | 40.45M |
CKPT Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 12.06M | 54.73M | 40.77M | 26.07M | 21.99M | 19.22M | 35.08M | 50.41M | -3.63M |
Operating activities | |||||||||
Net income | -51.84M | -62.62M | -56.67M | -23.08M | -24.71M | -36.36M | -22.67M | -22.46M | -13.89M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 324K | 0 |
Stock-based compensation expense | 2.89M | 2.92M | 3.13M | 2.78M | 3.12M | 0 | 3.11M | 3.86M | 3.25M |
| Deferred income tax benefit | 2.89M | 2.92M | 3.13M | 2.78M | 3.12M | 0 | 3.11M | 3.86M | 3.25M |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 73K | -56K | 3K | 6K | 1.50M | -1.20M | 490K | -756K | -65K |
Inventories | 0 | 56K | -3K | -6K | -1.50M | 0 | 0 | 0 | 0 |
Accounts payable | -5.07M | -4.62M | 18.76M | -833K | -5.04M | 6.72M | 2.69M | 1.88M | 0 |
Cash generated by operating activities | -47.59M | -57.55M | -26.30M | -16.55M | -21.37M | -25.80M | -15.46M | -9.95M | -1.10M |
Investing activities | |||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | 0 | 0 | 0 | 0 | -400K | -3.16M | -2.52M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | -400K | -3.16M | -2.52M |
Financing activities | |||||||||
Common Stock Issued | 33.62M | 17.62M | 41.27M | 33.26M | 27.57M | 0 | 0 | 570K | 51.49M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.79M | 2.55M |
Cash used in financing activities | 40.45M | 14.88M | 40.26M | 31.24M | 25.45M | 28.57M | 0 | -2.22M | 54.05M |
Net Change In Cash | -7.14M | -42.66M | 13.96M | 14.69M | 4.08M | 2.77M | -15.86M | -15.33M | 54.05M |
Cash at end of period | 4.92M | 12.06M | 54.73M | 40.77M | 26.07M | 21.99M | 19.22M | 35.08M | 50.41M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |